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Abstract: Long-acting muscarinic antagonist (LAMA) or long-acting β2-agonist (LABA) 
bronchodilators and their combination are recommended for the maintenance treatment 
of chronic obstructive pulmonary disease (COPD). Although the efficacy of LAMAs and 
LABAs has been well established through randomized controlled trials (RCTs), questions 
remain regarding their cardiovascular (CV) safety. Furthermore, while the safety of LAMA 
and LABA monotherapy has been extensively studied, data are lacking for LAMA/LABA 
combination therapy, and the majority of the studies that have reported on the CV safety 
of LAMA/LABA combination therapy were not specifically designed to assess this. Evalu-
ation of CV safety for COPD treatments is important because many patients with COPD 
have underlying CV comorbidities. However, severe CV and other comorbidities are often 
exclusion criteria for RCTs, contributing to a lack in external validity and generalizability. 
Real-world observational studies are another important tool to evaluate the effectiveness 
and safety of COPD therapies in a broader population of patients and can improve upon 
the external validity limitations of RCTs. We examine what is already known regarding 
the CV and cerebrovascular safety of LAMA/LABA combination therapy from RCTs and 
real-world observational studies, and explore the advantages and limitations of data derived 
from each study type. We also describe an ongoing prospective, observational, comparative 
post-authorization safety study of a LAMA/LABA combination therapy (umeclidinium/
vilanterol) and LAMA monotherapy (umeclidinium) versus tiotropium, with a focus on the 
relative merits of the study design.
Keywords: real-world observational study, cardiovascular, cerebrovascular, safety, 
umeclidinium, vilanterol
Introduction
Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and 
mortality, accounting for approximately three million deaths worldwide in 2012.1,2 
As COPD is characterized by persistent airflow limitation, long-acting muscarinic 
antagonists (LAMA) or long-acting β2-agonist (LABA) bronchodilators are recom-
mended treatment options.1 Bronchodilator monotherapy with LAMAs improves 
lung function and health status, and prevents exacerbations compared with placebo.3–5 
Combination therapy with LAMAs and LABAs exert complementary bronchodilatory 
effects, resulting in greater improvements in lung function compared with long-acting 
bronchodilator monotherapies.4,6–10 These dual combination bronchodilators also 
improve symptoms and health status, and reduce exacerbation risk to a greater extent 
than monotherapies or inhaled corticosteroid/LABA combinations.6,7,10,11
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Due to their mechanisms of action, both LAMAs and 
LABAs have the potential to cause cardiac-related adverse 
events (AEs). LAMAs suppress parasympathetic control of 
heart rate (HR) and LABAs stimulate sympathetic control 
of HR. These effects serve to raise HR with the potential 
to cause cardiac arrhythmias, myocardial infarction (MI), 
stroke, and sudden death in susceptible patients.1,12–15 When 
administered as combination therapy, LAMAs and LABAs 
are often combined using the same doses as for monotherapy. 
Thus, hypothetically, an increase in cardiovascular (CV) AEs 
compared with monotherapy cannot be excluded.
Randomized controlled trials (RCTs) are considered 
the gold standard study design for gaining evidence for 
regulatory approval. Real-world observational studies are 
often non-interventional in nature and may be prospective 
or retrospective in design. They are conducted in wider 
patient populations who have a range of demographics and 
characteristics and are important for monitoring the effects of 
therapies outside of the controlled setting. This is particularly 
important in COPD, where CV comorbidities are prevalent,16 
but are frequently an exclusion criterion for participation in 
RCTs,17–20 an issue that has been coined the “COPD trial 
paradox”.12 Here, we review the available evidence from 
RCTs and real-world observational studies regarding the 
CV and cerebrovascular safety of LAMA/LABA combina-
tion therapy versus monotherapy in COPD. We also include 
a special focus on an ongoing prospective, observational, 
comparative post-authorization safety (PAS) study of the 
LAMA/LABA combination therapy, umeclidinium (UMEC)/
vilanterol (VI), or UMEC monotherapy versus the LAMA 
monotherapy, tiotropium (TIO).
evidence from COPD RCts
Although the CV and cerebrovascular risk of LAMA and 
LABA monotherapies have been extensively examined in 
RCTs, relatively few studies have reported on the safety 
of LAMA/LABA combination therapies. RCTs that have 
reported on the CV and cerebrovascular safety of LAMA/
LABA combination therapy are described in Table 1. Further-
more, the studies that do report on the CV and cerebrovascular 
safety of LAMA/LABA combinations were not necessarily 
powered to study these outcomes, with the exception of Van de 
Maele et al21 the primary outcome of which was change from 
baseline in 24-h mean HR. Overall, the available evidence 
from RCTs has not shown any clinically significant increase 
in CV or cerebrovascular risk for the LAMA/LABA combi-
nations UMEC/VI,5,7,8,10,22–26 TIO/olodaterol,17,27,28 aclidinium/
formoterol,29,30 or indacaterol/glycopyrronium6,21,31–33 versus T
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Cardiovascular safety of lAMA/lABA combination therapy in COPD
monotherapy or placebo (Table 1). Indeed, one study 
reported that the incidence of atrial arrhythmias was similar 
between UMEC/VI 125/25 µg and placebo, but had a 2% 
greater incidence with UMEC 125 µg compared with pla-
cebo. Additionally, the overall incidence of CV AEs with 
UMEC/VI 125/25 µg was lower compared with UMEC 
125 µg or placebo, although because the event rate was 
low and the study not powered to detect these treatment 
differences in this endpoint, these results should be inter-
preted with caution.8
Advantages and limitations of COPD RCts
RCTs typically have high internal validity due to the ran-
dom allocation of patients to treatment groups, minimizing 
indication bias and confounding, as well as reducing biased 
reporting of endpoints. Additionally, a placebo/control arm 
can be used to measure the impact and remove any imbalance 
of the patient- and investigator-related Hawthorne effects (the 
phenomenon where individuals modify or improve aspects 
of their behavior in response to being observed)34 across 
treatment arms. The use of precise inclusion and exclusion 
criteria in RCTs also minimizes the effect of confounding 
factors such as patient comorbidities.35 However, exclusion 
criteria are used to exclude high-risk patients. For example, 
the TIOtropium Safety and Performance In Respimat (TIO-
SPIR) safety study targeting comorbid patients excluded 
the highest risk patients, such as those with previous MI, 
New York Heart Association class III or IV heart failure, or 
unstable or life-threatening arrhythmia.36 The high internal 
validity of RCTs allows treatment effects to be reliably 
determined. Consequently, RCTs are considered the gold 
standard for evaluating the efficacy of novel therapies to 
obtain regulatory approval.37
However, trial results need to be generalizable and suitable 
for extrapolation to a wider patient population to be clini-
cally useful. There are several reasons why RCTs in COPD 
have often lacked external validity. COPD studies often 
enforce exclusion criteria based on age (an upper age limit of 
70–75 years is common), disease severity (often excluding 
patients with mild airflow and very severe obstruction; forced 
expiratory volume in 1 second [FEV
1
] 80% predicted and 
30% predicted, respectively), comorbid conditions that 
potentially cause excessive risk for AEs, background mainte-
nance therapy use, or long-term oxygen therapy.38 The result-
ing patient populations are homogeneous but less generalizable 
to the wider heterogeneous COPD patient population.39,40
COPD has an established association with CV and other 
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secondary care referral study had 1 comorbid condition and 
over half had 4 comorbid conditions.41 Although common 
in the general COPD patient population, such comorbidities 
are frequently exclusion criteria in RCTs.12,17–20,35 Thus, there 
is a mismatch between a real-life COPD patient population 
and the subset of patients that would fit into the criteria used 
by RCTs.42–45 A postal survey was conducted in 2002–2005 in 
patients with COPD in New Zealand to determine eligibility 
for inclusion in any one of 18 previously conducted RCTs 
cited in the Global Initiative for Chronic Obstructive Lung 
Disease (GOLD) guidelines. The study found that eligibility 
ranged from 0% to 20% in all subjects with COPD and from 
0% to 9% in those patients receiving treatment for COPD 
with inhaled or oral steroids, or bronchodilators. These results 
demonstrate that the external validity of the major RCTs on 
which the GOLD treatment guidelines was based is low.46 
Similarly, two other analyses each demonstrated that just 
17% of a real-life COPD patient population would fit the 
criteria commonly used in RCTs in COPD.42,44
More recently, Kruis et al45 evaluated the external valid-
ity of six large industry-sponsored COPD trials (ISOLDE, 
TRISTAN, TORCH, UPLIFT, ECLIPSE, and POET-COPD), 
on which current COPD treatment guidelines are largely 
based. Compared with data from seven large European pri-
mary care databases, the population included in these RCTs 
was younger, predominantly male, with worse lung function 
and poorer quality of life. There was also a large difference in 
the disease severity (GOLD) distribution of patients enrolled 
in the RCTs versus the primary care database. For example, 
no patients with COPD with mild severity (GOLD I) were 
included in the RCTs, while patients with severe COPD 
(GOLD III) were overrepresented in the industry-sponsored 
studies versus the primary care population (44.5% vs 21%, 
respectively). Furthermore, baseline data on exacerbations 
suggested overrepresentation of patients with prior exacerba-
tions in the RCTs compared with the primary care population. 
Overall, it was shown that the proportion of patients from 
the primary care population that would be eligible to be 
included in the industry-sponsored RCTs ranged from 17% 
(TRISTAN) to 42% (ECLIPSE and UPLIFT).
Other factors that impact the external validity of RCTs 
relate to the trial setting (primary, secondary, or tertiary care), 
the health care system, and the country in which the trial is 
conducted.35 Even where health care systems are similar, other 
differences such as racial demographics, disease susceptibil-
ity, and natural history of the disease can influence external 
validity.35 Furthermore, differences between health care 
systems can affect hospital admissions, a factor that defines 
a COPD exacerbation as severe. However, the threshold for 
hospitalization differs between countries. For example, an 
adjusted 10-fold difference in respiratory disease-related 
hospital admissions has been reported across 31 European 
countries, being highest in Eastern Europe and Germany, and 
lowest in France, Portugal, UK, and Scandinavia.47
evidence from COPD real-world 
observational studies
Data from real-world observational studies reporting on 
LAMA/LABA combination therapy in COPD are currently 
lacking. Recently, a real-world study of patients included 
in the Registre de Données en Santé Pulmonaire database, 
which records information on Canadian patients with asthma 
or COPD, compared AEs associated with LAMA or LABA 
monotherapy use and LAMA/LABA combination use in 
patients with COPD. However, the study did not specifically 
report on CV and cerebrovascular AEs.48 Indeed, to date, we 
are not aware of any real-world observational studies that 
have specifically assessed the CV and cerebrovascular risk 
of LAMA/LABA combination therapy in COPD.
Advantages and limitations of COPD 
real-world observational studies
Real-world observational studies are designed to more closely 
reflect routine clinical practice and thus do not exclude 
patients with comorbidities associated with COPD or have 
further limitations with inclusion criteria such as upper age 
limit or smoking history. In contrast to RCTs, observational 
studies include a wider selection of patients and focus on 
balancing the risks and benefits of treatments.37 In contrast to 
the internal validity achieved in RCTs, the main advantage of 
real-world observational studies is their higher external valid-
ity, generally enrolling a wide range of patients across differ-
ent treatment settings.34,37 Real-world data from observational 
studies can also provide evidence of effectiveness to support 
health care decisions49 and assist health care policy makers 
in dealing with coverage and reimbursement decisions when 
evaluating the cost effectiveness of a treatment.50,51 Real-
world observational studies also ensure that drug safety is 
monitored in a broad population of patients.
Prospective non-interventional studies, such as DAC-
CORD registry, or the open-label pragmatic trial called 
the Salford Lung Study are examples of large observa-
tional COPD studies generating real-world evidence.49,52 
DACCORD is an ongoing 2- to 4-year real-world study 
being conducted in over 6,000 patients in ~500 primary 
and secondary care practices in Germany. Patients fall into 
two groups, one treated according to standard of care with 
a glycopyrronium-containing regimen and another group 
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treated according to standard of care without glycopyrronium. 
The study focuses on patient-related outcomes, time to first 
exacerbation, frequency of exacerbations, and lung function 
variables. The main strengths of the DACCORD study are the 
large size of study population, the long-term follow-up period, 
the broad inclusion criteria, and the implementation of disease 
management program criteria, which aims to ensure that only 
patients with appropriate COPD diagnosis are enrolled.52 
The Salford Lung Study consists of two open-label Phase III 
pragmatic RCTs in asthma and COPD. It was designed to 
compare the real-world effectiveness of fluticasone furoate/
VI via inhaler (plus standard care) versus regular maintenance 
therapy (plus standard care) for COPD and asthma in routine 
primary care. Following randomization, patients receive stan-
dard care by their physician for 12 months and effectiveness 
and safety data were collected using electronic health records. 
The design strengths of the Salford Lung Study are that it is 
a large, prospective, randomized study with broad inclusion 
criteria, which allow it to bridge the gap between low exter-
nal validity RCTs and low internal validity non-randomized 
observational studies.49,53 One potential limitation of the 
study is the relatively high level of intervention required by 
regulatory authorities due to the randomized nature of the 
trial, as this undermines the real-world design of the study, 
impacting on the Hawthorne effect.
The main limitations with real-world studies, specifically 
observational studies (ie, without random subject allocation), 
are the effects of potential confounding by indication bias, 
where the most severe patients may preferentially receive 
certain treatments.39 Additionally, the lack of blinding in real-
world studies is generally considered a limitation. However, 
this reflects clinical practice where patients either receive 
treatment or nothing at all. Thus, the efficacy of treatment 
versus placebo, already proven in completed RCTs, is not the 
target outcome of observational studies. If a comparator inter-
vention already exists, then the usual standard of care may be 
a more appropriate comparator.37 Observational studies that 
are retrospective in nature use electronic records and these 
studies can be limited by the robustness and completeness 
of their data sources, such as inconsistent reporting of data 
on disease severity. Another important source of bias in real-
world observational studies is attrition bias. For example, in 
the DACCORD study, of the 6,000 patients initially included 
in the study, only 4,123 patients remained after 1 year.54
A PAS study of UMeC/VI combination 
therapy
There are a few studies with large patient populations that 
have specifically assessed the CV and cerebrovascular 
safety of LAMAs and LABAs, such as SUMMIT, TORCH, 
UPLIFT, and TIOSPIR.36,55–57 However, much of the avail-
able data assessing CV and cerebrovascular risk have come 
from non-prespecified AE analyses in RCTs, which may not 
have been powered for CV AEs.
The 201038 PAS study is a prospective real-world 
observational cohort study that aims to reflect the real-world 
experience of patients with COPD treated with UMEC/VI 
or UMEC in the post-approval setting. The primary objec-
tives of the study are to demonstrate the non-inferiority of 
UMEC/VI and UMEC alone versus TIO for the risks of MI, 
stroke, or heart failure, each based on an analysis of time to 
first event. The study will also quantify the incidence rate 
and frequency of MI, stroke, and heart failure for new users 
of UMEC/VI, UMEC, and TIO. The primary and secondary 
safety outcomes are presented in Table 2.
Study design
This study is a non-randomized, observational study being 
carried out in several European Union (EU) and non-EU 
countries that have UMEC/VI, UMEC, and TIO available on 
prescription. Patients are enrolled in the study at the time of 
receiving a new prescription for UMEC/VI, UMEC, or TIO. 
The decision to initiate treatment with UMEC/VI, UMEC, 
or TIO is made independently by the patient and their physi-
cian and is not mandated by the study design or protocol. All 
patients are followed from initiation of treatment until the 
required number of CV events has been observed in the study 
population. All patients are observed over a minimum of 
24 months, or until withdrawal of consent, loss to follow-up, 
or death (Figure 1). The estimated maximum duration of 
follow-up is between 2 and 5 years. Data on patients are 
collected at routine visits at least twice yearly, as well as at 
unscheduled visits as per normal standard of care. All data 
will be collected via electronic case report forms (eCRFs) 
from information routinely recorded in patient’s medical 
records or through patient self-report. Hospital discharge 
summaries will be requested by the investigator or site staff 
for all hospitalizations of enrolled patients. Data from these 
summaries will be captured on the eCRF and also used for 
adjudication of CV and cerebrovascular events. Written, 
informed consent was and will be obtained from all patients 
who participate in the study. The study was approved by 
Sächsische Landesärztekammer, Dresden, Germany and 
other relevant national, regional, or investigational center 
Ethics Committee/Institutional Review Boards, and is and 
will be performed in accordance with the International 
Conference on Harmonisation of Technical Requirements 
for Registration of Pharmaceuticals for Human Use Good 
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Table 2 Primary and secondary study safety outcomes in the 201038 Post-authorization Safety Study of UMeC/VI combination 
therapy
Primary study safety outcomes Secondary study safety outcomes
Time to first event of each of MI, stroke, and heart failure 
(new or acute worsening)
Time to first composite safety endpoint (MI, stroke, heart failure,  
or sudden cardiac death)
Incidence ratea of each of MI, stroke, and heart failure 
(new or acute worsening)
Incidence ratea of composite safety endpoint (MI, stroke, heart failure, 
or sudden cardiac death)
total number of events of each of MI, stroke, and heart 
failure (new or acute worsening)
Incidence ratea and total number events of hemorrhagic stroke, 
ischemic stroke, undefined stroke, and hospitalization for heart failure
Incidence ratea of serious pneumonia/lRtI
total number of events and event rate of all pneumonia/lRtI Aes
Mortality rate (all-cause, CV-related, and non-CV-related)
CV Aes of special interestb, drug-related Aes, all SAesc, and all deaths
Notes: aPer person year; bincluding transient ischemic attacks, angina, cardiac arrhythmias, acquired long-Qt interval, cardiac ischemia and hypertension; Caccording to 
MedDRA SOC and PT; All treatment comparisons of primary and secondary safety outcomes will be analyzed using hazard ratios for time to first event.
Abbreviations: Ae, adverse event; CV, cardiovascular; lRtI, lower respiratory tract infection; MedDRA, medical dictionary for regulatory activities; MI, myocardial 
infarction; Pt, preferred term; SAe, serious adverse event; SOC, system organ class; UMeC, umeclidinium; VI, vilanterol.
Figure 1 Study design for the new 201038 Post-authorization Safety Study of 
UMeC/VI combination therapy.
Note: *The follow-up period will be defined as the period between the prescription 
index date until the earliest of: date when the planned number of events has been 
reached, 14 days following date of discontinuation of initiated COPD medication, 
withdrawal from the study, conclusion of study follow-up or death.
Abbreviations: COPD, chronic obstructive pulmonary disease; hCP, health care 
practitioner; tIO, tiotropium; VI, vilanterol; UMeC, umeclidinium.
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Clinical Practice (ICH-GCP) guidelines and all applicable 
patient privacy requirements and the ethical principles out-
lined in the Declaration of Helsinki, 2013.
Study population
The study is enrolling ~7,800 patients from 700 study 
centers in selected EU member states and other non-EU 
countries where UMEC/VI, UMEC, and TIO are available 
on prescription. Enrollment in non-EU countries is capped 
at ~50%. Eligible patients are enrolled by primary care 
physicians and pulmonologists and are aged 18 years, 
with a clinical diagnosis of COPD verified by spirometry 
(defined as a post-bronchodilator FEV
1
/forced vital capacity 
ratio of 0.7) and initiating treatment with either UMEC/
VI, UMEC, or TIO. Key exclusion criteria include current 
participation in any interventional clinical trials; hypersen-
sitivity to UMEC, VI, TIO, or excipients; and maintenance 
treatment (defined as 60 days of continuous use) with 
a LAMA-containing medication during the 12 months 
prior to enrollment. At enrollment, detailed data on patient 
demographics, baseline characteristics, modified Medical 
Research Council and COPD assessment test questionnaire 
scores, disease comorbidities, and concomitant medication 
use are collected using an eCRF. Information is provided by 
the treating physician based on a combination of self-reported 
information from the enrolled patient and where available, 
supplemented by the patient’s electronic medical records. 
The study is event-driven, requiring at least 98 events for 
each of MI, stroke, and heart failure for each pair of treat-
ments (UMEC/VI vs TIO; UMEC vs TIO). Therefore, the 
number of patients that need to be enrolled will be updated 
as necessary throughout the study. The study has a 90% 
power to reject a non-inferiority margin of a hazard ratio of 
2.0 for each treatment pair for each outcome (MI, stroke, and 
heart failure). This is based on the requirement that the 95% 
confidence interval for the hazard ratio excludes 2.0.
Advantages and limitations of the study 
design
The study incorporates several important design features that 
aim to minimize the potential limitations of observational stud-
ies, such as potential confounding by indication bias or attrition 
bias, and the lack of blinding. Observational studies are often 
retrospective; however, enrollment in this study is prospective, 
allowing for robust data collection through eCRFs. The study 
aims to recruit a wide population of patients with COPD from 
different care settings. Eligible patients are enrolled by both 
primary care physicians and pulmonologists, which helps to 
ensure representation from different care settings. Patients 
“new” to therapy are defined as not having received LAMA 
maintenance therapy for 60 consecutive days during the 
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previous 12 months. This should minimize enrolled patient 
“survival” bias, where prevalent users of LAMAs that have 
survived are disproportionately represented in any treatment 
groups.58 This is particularly important for assessing whether 
mortality risk is affected by treatment. Specifically, it mini-
mizes the bias of prescription of two LAMAs (eg, UMEC/
VI added to TIO), which may unfortunately occur in error. 
However, this is also a potential limitation of the study as it 
excludes many patients, particularly as LAMA maintenance 
is the most frequently prescribed treatment for COPD in some 
countries, such as Germany.59 The requirement that patients 
must not have received LAMA maintenance therapy for 60 
consecutive days during the prior 12 months also limits the 
patients included, meaning that the enrolled population will 
not be fully representative of the wider COPD patient popula-
tion. However, patients can continue on existing maintenance 
treatments, which helps to reduce the potential for excluding 
patients with more severe disease. Also the factors that may 
be associated with treatment choice (and with risk of primary 
events) are documented to account for potential confound-
ing in propensity score analyses. Additionally, as follow-up 
does not require patients to return to their study center except 
for routine care, follow-up bias whereby patients with AEs 
are more or less likely to return to see their study physician 
is minimized by maintaining a low lost to follow-up rate 
(a rate of 5% is anticipated). Furthermore, to standardize 
the reporting of primary CV events (MI, stroke, or heart 
failure) between centers (which may adopt different inter-
pretations and event definitions), only events confirmed 
by the blinded adjudication committee are included. The 
expected event rates for MI, stroke, and heart failure are 98, 
108, and 168,60 although as the study is event-driven, recruit-
ment rates will be adjusted once the actual event rate in this 
population is known.
Conclusion
Both RCTs and real-world observational studies contribute 
important data regarding the efficacy, safety, and effective-
ness of COPD treatments. When evaluating a treatment effect 
it is important for health care practitioners to consider the 
generalizability of study findings to their patients. As both 
study types have inherent limitations, data from the pivotal 
COPD RCTs are complemented by real-world observational 
study data, which should both be evaluated to elucidate 
evidence of any treatment benefits and safety concerns. 
More research is needed to determine the effects of COPD 
treatments in patients who have been underrepresented in 
RCTs, such as women and patients with mild and very severe 
disease. Furthermore, the CV safety of COPD treatments in 
real-life patients, including those with comorbidities, should 
be further investigated, both in observational studies and 
more inclusive pragmatic RCTs. As there is hypothetically 
a potential for higher CV risk with dual bronchodilator 
treatment, the new 201038 PAS study documented here 
will provide data on the CV and cerebrovascular risks of 
the LAMA/LABA combination UMEC/VI, and the LAMA 
monotherapies UMEC and TIO in a real-world setting. The 
study design aims to reduce some of the common limitations 
of observational studies and to provide safety data for dual 
bronchodilator therapy in a more vulnerable COPD popula-
tion than those included in RCTs.
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